Biocon Ltd : History, Latest Updates, Milestones, Subsidiaries & Share Price
Company Overview
Biocon Ltd. is the pioneer in the biopharmaceutical industry of India and has been able to provide access to innovative medicines for patients worldwide. It was founded in 1978 by Kiran Mazumdar-Shaw and is headquartered in Bengaluru. The company has grown into a globally recognized biopharmaceutical enterprise with a portfolio of biosimilars, generics, and specialty pharmaceuticals that cater to more than 120 countries. Powered by innovation, Biocon has deep investments in research and development, with a product portfolio addressing diabetes, cancer, and autoimmune diseases through world-class biotechnology.
The financial performance and steady growth of the company reflect in the Biocon share price. Biocon share price had closed at Rs.399.95 each on both the NSE and BSE on November 24, 2025. The Biocon share price has oscillated between Rs.291 and Rs.406 in 2025, reflecting resilience and consistent investor interest amidst changing market dynamics. As of late 2025, Biocon had a market capitalization of about Rs.53,000 crore, with annual revenue of more than Rs.16,000 crore and a net profit of about Rs.762 crore, testifying to its strong position in the healthcare segment.
For investors and analysts, platforms like Enrich Money provide comprehensive real-time insights into Biocon share price, technical trends, future outlooks, and financial metrics. This empowers market participants to monitor Biocon's progress and make well-informed trading decisions. By combining scale, affordability, and scientific excellence, Biocon continues to set new standards in biopharma, thereby reinforcing its reputation among both healthcare professionals and stock market investors.
Recent Developments in 2025
In January 2025, Biocon strengthened its portfolio of biosimilars and outlined a strategic roadmap toward global market reach. This was on the back of steady early clinical trial progress, which is indicative of potential future revenues.
By March, Biocon announced approval and increased production capabilities for key biosimilar insulins, boosting confidence among investors. At the end of March, consolidated revenue at Biocon had posted a modest rise to support incremental gains in share price.
Results for Q1 FY26 declared in June 2025 reflected stable revenue growth and improvement in margins at Biocon. Expanding diabetes and oncology biosimilars paid off for the company, reflecting in improving profitability. All the financial metrics contributed to a bullish trend in the share price of Biocon.
In September, Biocon reported robust demand for biologics in North America and Europe, which supported a revenue growth of 20% year-over-year. The company also secured regulatory approvals for critical new drug candidates, strengthening its product pipeline.
October brought big news as the U.S. FDA granted interchangeable biosimilar status to one of Biocon's flagship insulin products, and this was widely expected to drive volume growth. This key regulatory development strengthened investor sentiment and thus impacted the Biocon share price.
Biocon announced strong financial results for Q2 FY26 in November, with a 9.1% quarter-over-quarter increase in total income to Rs.4388.5 crore and a nearly 49% surge in profit after tax to Rs.132.8 crore. The EBITDA was up by 29%, while the earnings per share also improved substantially. The good quarterly report supported continued investor confidence and kept the Biocon share price close to Rs.400 INR.
Evolution
1978: Biocon was set up in Bengaluru by Kiran Mazumdar-Shaw as an industrial enzymes manufacturing company. Initial operations were modest, with the company focusing on enzymes for various industries.
1998: Forayed into biopharmaceuticals. This marked a strategic transition for Biocon from industrial enzymes to health care. It became the first biotech company to launch an IPO on Indian exchanges; its market capitalization was less than Rs.100 crore at the time.
2004: First commercial biopharmaceutical products were launched by the company, including immunosuppressants and statins. Revenues crossed Rs.100 crore, establishing Biocon as a biotech innovator in India.
2010: Launched India's largest integrated insulin manufacturing facility, expanding into biosimilars, especially in the care for diabetes. At this time, the yearly revenue of Biocon was about Rs.400 crore.
2014: Forayed into monoclonal antibodies and oncology biosimilars with approvals for medicines like trastuzumab and bevacizumab biosimilars. Revenues crossed Rs.1,000 crore on account of market penetration in the international market.
2015: Syngene International, the Biocon arm dedicated to contract research, was listed publicly to underline corporate growth and diversification. Consolidated revenue crossed Rs.1,200 crore.
2018-19: Biocon scaled global biosimilar commercialization by entering critical markets of the U.S. and Europe; revenues approached Rs.2,500 crore as R&D spend increased substantially to fire pipeline expansion.
2020: Keeping its biosimilars focus in mind, Biocon carved out a separate entity called Biocon Biologics. Some key products, such as insulin glargine, were launched, with the company finding multiple regulatory approvals globally. Revenues soared above Rs.4,000 crore.
2023: Further global expansion with a strong focus on oncology and diabetes biosimilars; strategic partnerships improved market access. Reported annual revenues of around Rs.7,000 crore with improving profitability metrics.
2025: Biocon recorded revenues over Rs.16,000 crore at an all-time high, driven in large part by the growth of biosimilars and biologics. Quarterly results reflected profits rising nearly 50% year-over-year, while increased production scale and key regulatory milestones boosted investor confidence, pushing a Biocon share price nearing Rs.400.
Company Information
|
Company Information |
|
|
Trade Name |
Biocon Ltd. |
|
Founded year |
1978 |
|
Headquarters |
Bengaluru, Karnataka, India |
|
Industry |
Biopharmaceuticals and Biotechnology |
|
Chairman |
Kiran Mazumdar-Shaw |
|
Revenue |
Approximately Rs.16,000 crore (FY 2025) |
|
NSE code |
BIOCON |
|
BSE code |
532523 |
Milestones , Awards and Achievements
1978: Established Biocon in Bengaluru, which was to become India's pioneering biotechnology company, with the launch of industrial enzymes.
1998: First Indian biotech company to be listed on the stock exchanges, marking the opening of its capital markets journey and fostering a sense of investor trust.
2001: It became the first Indian company to be approved by the US FDA for the manufacture of Lovastatin, one of the world's best-selling drugs for lowering cholesterol.
2006: Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, enhancing its research and manufacturing capabilities manifold.
2010: Commissioned Asia's largest integrated insulin manufacturing facility to enable affordable diabetes care.
2013: Introduced Itolizumab, a novel biologic, for the advancement of autoimmune disease treatments related to psoriasis.
2014: Developed CANMA, India's first biosimilar trastuzumab, and made the advanced therapy for breast cancer more accessible and affordable.
2015: Syngene International, Biocon's contract research organization, was listed publicly - an important diversification step.
2016: Biocon received approval for its biosimilar insulin glargine pen in Japan, becoming the first Indian company to get such an approval.
2017: U.S. FDA approved biosimilar trastuzumab, marking a key milestone for global biosimilar acceptance; initiated operations of a major insulin manufacturing plant in Malaysia.
2018: Launched Pegfilgrastim, another key biosimilar, into the U.S. markets, thus strengthening its global footprint.
2020: Biocon Biologics was formed as a separate entity, dedicated only to biosimilars. It also got the approval for the Itolizumab treatment against COVID-19 in India.
2023: Won several awards within the industry for its best corporate governance and ESG excellence. Further expanded reach to more than 120 countries.
2025: Set record revenues crossing Rs.16,000 crore with strong profitability growth. Received key regulatory approvals, including U.S. FDA’s interchangeable biosimilar status for insulin glargine, boosting its market position and investor interest reflected in its Biocon share price.
News, Major Corporate Milestones & Announcements in 2025
Dividend actions in 2025
The board recommended a final equity dividend of Rs.0.50 per Biocon share for FY2024-25, which the shareholders approved at the AGM held in May 2025.
The dividend carried an ex-date and record date of 4 July 2025. The dividend yield depends on the current Biocon share price around Rs.375–Rs.395.
Capital actions
In April 2025, Biocon issued listed commercial papers largely to refinance existing borrowings. The company later fixed 18 September 2025 as the record date and completed a Rs. 600 crore buyback of these commercial papers on 19 September 2025, fully honoring the obligation and underlining balance-sheet strength.
Earnings and operating milestones
Operating revenue for Q2 FY26, reported November 2025, came in at about Rs.4,296 crore, up 20% year-on-year, with EBITDA at roughly Rs.928 crore, up 29%.
Consequently, profit before tax (before exceptionals) saw a considerable increase of approximately Rs.183 crore, over 150% YoY growth. Net profit was reported in the mid-Rs.80 crore range, supporting a firmer Biocon share price and improved sentiment around the biosimilars-led growth story
Strategic and business updates Growth in 2025 was led by the biosimilars business, which delivered around 25% year-on-year revenue expansion in Q2 FY26, helped by scale-up in key markets like the U.S. and Europe.
New biosimilars like denosumab, Bosaya and Aukelso, secured US FDA approvals with provisional interchangeability, improving Biocon's position in the high-value bone health and oncology segments.
Management commentary through results and investor communications highlighted continued focus on deleveraging, margin improvement, and disciplined R&D investment to support the medium-term pipeline.
Biocon Share Price
|
Company Name |
Sector |
Share Price Link |
|
Biocon Ltd |
Healthcare |
Conclusion
Biopharmaceutical company Biocon Ltd has built an impressive legacy in innovation and steady expansion, as reflected by the consistently strong Biocon share price. The firm is further strengthening its position in the leadership of affordable biosimilars and specialty medicines through research and global outreach. If looking to keep updated and ahead of the game, active investors can start using the Enrich Money ORCA app for accurate stock analysis and live prices, coupled with profound insight into financial data for the right investment decisions.
Frequently Asked Questions
What is the present share price of Biocon limited?
Biocon limited share price was seen concluding around Rs.400 in late 2025, reflecting steady investor confidence.
How has the share value of Biocon changed over a period of time?
Biocon share value has gained significantly, driven by strong sales of biosimilars and new healthcare products.
Where can I check the Biocon stock price today?
You can track Biocon share price today live on platforms such as Enrich Money to get updates in real-time.
What is the Biocon share price target tomorrow, and what will be the Biocon share price target 2030?
Though the short-term targets are fluctuating, analysts foresee promising long-term growth for Biocon with optimistic 2030 share price forecasts.
What are the recent developments which would affect Biocon share price today?
Recent regulatory approvals and strong quarterly results in 2025 have positively influenced the share price of Biocon today.
Check our ORCA app to analyze stocks' performance:
Biocon Ltd. Technical Analysis
Biocon Ltd. Financial Statements
Biocon Ltd. Shareholding Pattern
Biocon Ltd. Latest Corporate News
Biocon Ltd. Stock/Company Overview
Related Stocks
Sun Pharmaceutical Industries Ltd.
Glaxosmithkline Pharmaceuticals Ltd.
Disclaimer: This blog is dedicated exclusively for educational purposes. Please note that the securities and investments mentioned here are provided for informative purposes only and should not be construed as recommendations. Kindly ensure thorough research prior to making any investment decisions. Participation in the securities market carries inherent risks, and it's important to carefully review all associated documents before committing to investments. Please be aware that the attainment of investment objectives is not guaranteed. It's important to note that the past performance of securities and instruments does not reliably predict future performance.
